The dogs who might slow down Alzheimer's

Doges Editorial · 2026-06-09 · 6 min read

A 60 Minutes report on the Dog Aging Project reveals that dogs without exercise are six times more likely to develop dementia — and that rapamycin may be changing what happens inside their aging brains.

Ralph forgot about the treat in seconds. He wandered off from the exam table, found a piece of lint on the floor, and gave it his complete attention. His owner Tara watched from across the room. That moment — a dog ignoring food, absorbed by something meaningless — was the test, and Ralph had just failed it.

The diagnosis came in February 2025: cognitive dysfunction syndrome, the canine equivalent of Alzheimer's disease. It builds slowly. The same corner sniffed three times in a row. The morning routine that no longer holds. A familiar treat, overlooked. Ralph was ten years old, and his brain was unraveling the way all aging brains eventually do — in dogs, in people, through the same cascading inflammation in the same kinds of neural tissue. That parallel is, it turns out, the point of the research his life has now joined.

The disease is more common than most owners realize. Veterinary studies estimate that 28 percent of dogs aged 11 to 12 show at least one sign of cognitive decline — rising to 68 percent of dogs aged 15 to 16. Yet as recently as 2010, fewer than 2 percent of affected dogs had received a formal veterinary diagnosis, because owners and veterinarians alike tend to attribute the changes to normal aging. The forgetting gets overlooked.

Inside the project watching 50,000 dogs age

Shortly after his diagnosis, Ralph was enrolled in the Dog Aging Project — a collaboration between hundreds of veterinary clinics, dog owners, and researchers studying how dogs age in real time. As of June 2026, more than 50,000 dogs across the United States are participating. Their blood samples, behavioral tests, owner surveys, and veterinary records flow into a shared public database. The project's work has now produced more than 50 peer-reviewed scientific papers. CBS News' 60 Minutes visited the Colorado State University site and aired its report on June 7, 2026 — a rare mainstream account of what that data is actually showing.

Some findings are intuitive. Dogs that live with other dogs appear to suffer from fewer diseases overall. But one finding is striking in its specificity: dogs that don't get regular exercise have a six times greater chance of developing dementia than dogs that remain active. Not modestly more likely. Not twice as likely. Six times.

Cancer, dementia, all these diseases that we see as humans age occur in dogs.

— Stephanie McGrath, veterinarian, Colorado State University College of Veterinary Medicine

What rapamycin does to an aging brain

The most carefully watched element of the project involves rapamycin — already used in humans to prevent organ transplant rejection and shown in laboratory mice to extend life expectancy by sixty percent. The drug works by suppressing a protein complex called mTOR, which governs how cells process nutrients and stress signals. When mTOR is inhibited, cells accelerate autophagy — a form of self-cleaning that clears out damaged proteins, including the amyloid plaques that accumulate in aging dog and human brains alike. The same molecular pathway; the same debris.

To understand whether rapamycin might slow cognitive decline in dogs, Colorado State molecular biologist Julie Moreno ran a small but precise pilot study: twelve dogs with signs of cognitive decline, half given rapamycin daily, half given a placebo.

As each dog died, Moreno examined its brain. The results surprised her. The dogs given rapamycin showed noticeably fewer microglial cells — the immune cells that generate inflammation in the aging brain, and whose excess is closely tied to dementia in humans. Ralph's brain, when it was studied, matched the pattern. Two other dogs in the rapamycin group showed the same thing. The placebo dogs did not.

If it works in a dog, and it's safe, and it's helping their cognition, then maybe it would help humans.

— Julie Moreno, molecular biologist, Colorado State University

Moreno's pilot was designed to look inside aging brains, not measure lifespan. The formal lifespan test is now underway. TRIAD — the Test of Rapamycin in Aging Dogs — is enrolling 580 healthy dogs aged at least seven years at sites across the U.S., backed by a $7 million NIH grant awarded in December 2024. Its published study design, by Coleman et al. in GeroScience (2025), describes it as 'the first rigorous test of a pharmacologic intervention against biological aging with lifespan and healthspan metrics as endpoints to be performed outside of the laboratory in any species.' Dogs receive once-weekly rapamycin for one year, then are monitored for two more — long enough to detect a nine percent change in lifespan.

The startup betting on one more healthy year

A parallel clinical trial is being run by Loyal, a San Francisco biotech startup founded in 2019 by Celine Halioua, then 29. The company is developing a separate drug — the specific compound has not been publicly disclosed — with a deliberately modest goal: add roughly one additional healthy year to a dog's life. Not immortality. Not a cure. Just more time in good condition.

Loyal's drug passed a significant FDA safety milestone in 2025. Data from more than four hundred dogs showed it appears safe for its intended use, allowing the larger efficacy trial to proceed. If approved, possibly by late 2026, it would be the first veterinary drug explicitly cleared to extend a dog's healthspan. Halioua imagines it as something routine — taken preventatively, before the decline begins, the way a statin is taken before a heart attack.

My vision is that this is a daily beef-flavored pill given preventatively to keep them healthier longer, similar to a statin for older Americans.

— Celine Halioua, founder of Loyal

Two minds aging at once

Pat Schultz's husband Bill died from Alzheimer's disease two years before she enrolled her dog Murphy in the Dog Aging Project. She won't know for several more years whether Murphy received rapamycin or a placebo. But she's been watching him with the specific attention of someone who already understands what it means to care for a mind that is quietly slipping — the small rituals that help, the patience that the moment requires, the way presence becomes the only real medicine available.

The thing I notice is that they both need to be loved and cared for. Just holding Bill's hand and patting his hand was enough just to decrease that anxiety, decrease that fear that was there. And that works with Murphy, too.

— Pat Schultz, Dog Aging Project participant

Why dogs are the right model

Dogs age faster than humans — a ten-year-old dog is already well into the second half of its life — which means researchers can observe years of aging biology within a single trial window. They also share our environments: our city air, our processed food, our sedentary-to-active lifestyles. Their cancers and dementias develop through mechanisms that closely parallel our own. Dr. Dirk Keene, a neuropathologist at the University of Washington and part of the Dog Aging Project, put it directly: the goal is to find the right model for human disease, and in dogs, there is a real opportunity.

Matt Kaeberlein, who co-leads the project, has said that much of what governs aging — the signaling pathways, the inflammatory cascades, the cellular mechanisms — works the same way in dogs as it does in people. The project was designed around that insight, and the data is beginning to confirm it.

The one finding you can use today

The six-times-greater dementia risk for inactive dogs is perhaps the most immediately applicable finding from the project's five years of data. It doesn't require a clinical trial to act on. It doesn't depend on a drug that hasn't been approved yet. McGrath's advice for aging dogs — and, implicitly, for dogs of any age — comes down to four plain words: keep them moving, thinking.

Ralph is gone now. But he ended up in the study. Fifty thousand dogs are still in it. And somewhere in the data they're generating — the walks logged, the treat-response tests, the MRI scans of aging neural tissue — is information that might eventually help both of the species that take that morning loop together, and notice things, and forget things, and keep going.